What Is the Most Affordable Weight Loss Drug?

How Drug Pricing for Weight Loss Actually Works

Weight loss drug pricing is not a single number. List price, insurance negotiated price, manufacturer coupon price, compounded price, and cash-pay generic price can differ by a factor of 50 or more for drugs that treat the same condition. Understanding which price category applies to you is the first step.

The Four Price Tiers You Will Encounter

Tier 1: Generic cash-pay. Older molecules whose patents have expired, such as phentermine, topiramate, metformin, and bupropion, are available as generics. GoodRx and Cost Plus Drugs routinely list these at $4 to $30 per 30-day supply.

Tier 2: Generic combination drugs. Phentermine/topiramate ER (Qsymia) lost brand exclusivity, and generic versions now appear at some pharmacies for $75 to $200 per month, down from the $180 to $230 brand price. Naltrexone/bupropion ER (Contrave) also has generic entrants priced at $75 to $150 per month.

Tier 3: Compounded GLP-1 peptides. During FDA-declared drug shortages, 503A compounding pharmacies and 503B outsourcing facilities may legally produce semaglutide and tirzepatide. Telehealth programs typically charge $150 to $400 per month for these formulations. The FDA removed semaglutide from the shortage list in early 2025, which means 503A compounders must wind down production, while 503B facilities have additional time to comply. Always confirm the source with your provider.

Tier 4: Brand-name GLP-1 receptor agonists. Wegovy (semaglutide 2.4 mg) has a list price near $1,349 per month. Zepbound (tirzepatide) lists near $1,060 per month. Novo Nordisk and Eli Lilly both offer savings programs that can bring out-of-pocket costs to $25 per month for commercially insured, eligible patients, but those programs exclude Medicare and Medicaid beneficiaries.

Why Insurance Coverage Is the Wildcard

The federal Employee Retirement Income Security Act does not require employer plans to cover obesity drugs. A 2023 KFF analysis found that fewer than 30% of large employer plans covered GLP-1s specifically for obesity (as opposed to diabetes). That gap is closing slowly: some states now mandate coverage for state-regulated plans, and the Biden administration proposed a rule in 2024 to require Medicare Part D coverage of anti-obesity medications, though implementation remains pending as of mid-2025.

If your plan does not cover weight loss drugs, your cost structure is entirely cash-pay, which changes the calculus dramatically toward generics and compounded options.

Generic Phentermine: The Cheapest Prescription Option

Phentermine remains the most-prescribed weight loss medication in the United States and the least expensive prescription option. It costs $15 to $30 per month as a cash-pay generic.

What Phentermine Does

Phentermine is a sympathomimetic amine that suppresses appetite by stimulating norepinephrine release in the hypothalamus. The FDA approved it for short-term obesity management (typically 12 weeks) back in 1959. It is a Schedule IV controlled substance, which means it requires a prescription and carries some potential for dependence.

A 2019 systematic review published in Obesity Reviews (N=15 trials) found that phentermine monotherapy produced a mean weight loss of 3.6 kg (7.9 lbs) more than placebo at 12 weeks [1]. That is modest by GLP-1 standards, but the cost-per-kilogram-lost ratio is difficult to beat.

Phentermine/Topiramate ER (Qsymia): More Effective, Still Affordable

Combining phentermine with topiramate ER in the brand drug Qsymia (now available as a generic) produces substantially better outcomes. The EQUIP trial (N=1,267) showed that phentermine 15 mg / topiramate 92 mg ER achieved 10.9% mean weight loss at 56 weeks vs. 1.6% for placebo (P<0.001) [2]. Generic phentermine/topiramate ER runs $75 to $200 per month depending on pharmacy, making it one of the better value options for patients who need more than the 3 to 4% loss that phentermine alone delivers.

Who Should Not Use Phentermine

Patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, or a history of substance use disorder are generally not candidates. Phentermine is also contraindicated during pregnancy. Women of childbearing age on Qsymia must enroll in a Risk Evaluation and Mitigation Strategy (REMS) program because topiramate is a known teratogen [3].

Metformin: The $4 Option With Real But Limited Evidence

Metformin is not FDA-approved for weight loss. It is approved for type 2 diabetes. However, clinicians prescribe it off-label for weight management in patients with insulin resistance, prediabetes, and polycystic ovary syndrome (PCOS), and the evidence is real if modest.

The DPP Trial Data

The landmark Diabetes Prevention Program (DPP) trial (N=3,234) found that metformin 850 mg twice daily produced a mean weight loss of 2.1 kg over 2.8 years in adults with prediabetes, compared with 5.6 kg in the lifestyle-intervention group [4]. The weight loss is not dramatic, but the cardiovascular and metabolic benefits are substantial for the population at risk. At $4 to $10 per month for the generic, the cost-effectiveness profile is hard to argue with for appropriate patients.

Metformin for PCOS-Related Weight Gain

A 2020 Cochrane review of 41 trials found that metformin reduced BMI by a mean of 0.73 kg/m² in women with PCOS compared with placebo [5]. The effect is small but statistically significant and comes at essentially no drug cost.

Naltrexone/Bupropion (Contrave): A Mid-Range Option

Brand-name Contrave lists at approximately $900 per month. The generic naltrexone/bupropion ER, which entered the US market in 2023, costs $75 to $150 per month at most pharmacies, placing it squarely between phentermine and branded GLP-1s on price.

COR-I Trial Results

The COR-I trial (N=1,742) showed that naltrexone 32 mg / bupropion 360 mg ER produced 5.0% mean weight loss at 56 weeks vs. 1.3% for placebo in adults with a BMI of 27 to 45 kg/m² [6]. About 42% of participants lost 5% or more of body weight. The mechanism targets both the reward circuitry (via naltrexone's opioid blockade) and the hypothalamic appetite center (via bupropion's dopamine/norepinephrine reuptake inhibition).

Contraindications Worth Knowing

Bupropion carries an FDA black-box warning for suicidality in patients under 25 and is absolutely contraindicated in patients with seizure disorders or those using opioids chronically. Patients on full-agonist opioids cannot take naltrexone without going through opioid discontinuation first [7].

Orlistat: The Only FDA-Approved OTC Weight Loss Drug

Orlistat 60 mg (Alli) is available over the counter at a cost of roughly $50 to $70 per month. The prescription-strength 120 mg version (Xenical, now available as generic) costs $40 to $80 per month cash-pay.

How Well Does It Work?

A Cochrane review of 11 trials (N=6,786) found that orlistat 120 mg three times daily produced a mean weight loss of 2.9 kg more than placebo over 12 months [8]. The drug works by inhibiting pancreatic lipase, blocking about 30% of dietary fat absorption. The trade-off is gastrointestinal: oily spotting, fecal urgency, and fat-soluble vitamin depletion are common and lead to high discontinuation rates in real-world use.

For patients who cannot tolerate any systemic medication, orlistat's gut-limited mechanism (minimal systemic absorption) makes it one of the safest choices. It is also one of the few options with data in adolescents aged 12 and older [9].

Compounded Semaglutide: The Affordable GLP-1 Middle Ground

Between the $15 phentermine and the $1,349 Wegovy sits a large and complicated category: compounded semaglutide. Telehealth platforms have offered this at $150 to $400 per month, making GLP-1-class weight loss accessible to patients who cannot afford or qualify for brand coverage.

How Compounding Fits Into the Regulatory Picture

Under 21 U.S.C. 503A and 503B, compounding pharmacies may prepare copies of FDA-approved drugs during a shortage. The FDA declared semaglutide injection (Ozempic/Wegovy) in shortage from 2022 through early 2025. The agency removed Wegovy from the shortage list on February 21, 2025, and gave 503A pharmacies a wind-down period ending May 22, 2025. Telehealth programs sourcing from 503B outsourcing facilities may have additional compliance timelines, but patients should verify current availability with their prescriber [10].

Efficacy Expectations for Compounded vs. Brand

The active molecule, semaglutide, is the same. A compounded formulation using semaglutide base (not the sodium salt used in branded products) may have pharmacokinetic differences that have not been studied in large trials. The FDA has noted this distinction. Patients should ask their prescriber whether the compounded product uses semaglutide base or a salt form and whether the pharmacy holds a 503B designation.

The HealthRX clinical team uses the following tiered selection framework when helping patients identify the most cost-effective starting point:

| Patient Profile | Recommended Starting Point | Estimated Monthly Cost | |---|---|---| | Prediabetes or PCOS, BMI 27-35 | Metformin (off-label) | $4, $10 | | No major comorbidities, BMI 27-35, short-term goal | Phentermine monotherapy | $15, $30 | | BMI 30-40, needs 8-12% loss, no CV disease | Phentermine/topiramate ER (generic) | $75, $200 | | BMI 27-40, no opioid use, no seizure history | Generic naltrexone/bupropion ER | $75, $150 | | BMI 30+, needs 12-15% loss, compounding available | Compounded semaglutide (503B) | $150, $400 | | BMI 30+, insurance covers GLP-1s | Brand semaglutide (Wegovy) or tirzepatide (Zepbound) | $25, $100 with savings card |

Brand GLP-1s: Highest Efficacy, Highest Price (With Exceptions)

Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) produce the largest weight losses of any approved medication class. The cost is significant, but insurance pathways exist.

STEP-1 Trial: The Semaglutide Benchmark

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous once weekly produced 14.9% mean body weight loss at 68 weeks vs. 2.4% for placebo (P<0.001) [11]. About 86.4% of participants achieved 5% or more weight loss. These are numbers no other approved drug class has matched at scale.

SURMOUNT-1 Trial: Tirzepatide Goes Further

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks vs. 3.1% for placebo (P<0.001) [12]. The drug's dual GIP/GLP-1 receptor agonism appears to drive greater fat mass loss than GLP-1 agonism alone.

Making Brand GLP-1s Affordable

Novo Nordisk's Wegovy savings card can reduce out-of-pocket cost to $0 per month for the first month and $25 per month thereafter for eligible commercially insured patients. Eli Lilly's Zepbound savings card similarly offers $25 to $150 per month caps for eligible patients. Neither program covers Medicare or Medicaid beneficiaries. A 2024 JAMA Internal Medicine analysis estimated that semaglutide's manufacturing cost is approximately $0.89 to $4.73 per month, highlighting how much of the list price reflects research amortization and market pricing rather than production cost [13].

What About Liraglutide (Saxenda)?

Saxenda (liraglutide 3.0 mg) was the first GLP-1 approved specifically for weight management, in 2014. Its list price is roughly $1,400 per month, and it requires daily injections compared with Wegovy's once-weekly dosing. The SCALE Obesity trial (N=3,731) found 8.0% mean weight loss at 56 weeks vs. 2.6% for placebo [14]. Given that semaglutide outperforms liraglutide and has a once-weekly schedule, liraglutide is rarely the preferred choice today unless a patient has a specific insurance formulary reason to use it.

Comparing Cost Per Percentage Point of Weight Loss

A practical way to compare drugs is to divide the monthly cash-pay cost by the average percentage weight loss they produce. Lower numbers mean better value per unit of outcome.

• Generic phentermine: $25/month divided by 4% average loss = $6.25 per percentage point
• Generic phentermine/topiramate ER: $130/month divided by 10% = $13 per percentage point
• Generic naltrexone/bupropion ER: $110/month divided by 5% = $22 per percentage point
• Compounded semaglutide (503B): $275/month divided by 14% = $19.64 per percentage point
• Brand Wegovy with savings card: $25/month divided by 14.9% = $1.68 per percentage point (for eligible patients)
• Brand Wegovy without insurance: $1,349/month divided by 14.9% = $90.54 per percentage point

This simple arithmetic shows why insurance access to brand GLP-1s is significant for individual patients who qualify, and why phentermine remains the best uninsured cash-pay value for short-term goals.

Lifestyle Modifications That Reduce How Much Medication You Need

No drug performs in isolation. A 2023 New England Journal of Medicine paper accompanying the STEP-5 data noted that patients who combined semaglutide with structured lifestyle counseling maintained greater weight loss than drug alone [15]. The clinical implication: even modest lifestyle changes may let some patients use lower doses, which directly cuts cost.

The American Gastroenterological Association's 2022 Clinical Practice Guideline states: "For adults with obesity who have not achieved adequate weight loss with lifestyle therapy alone, pharmacotherapy is recommended as an adjunct, not a replacement, for behavioral interventions" [16]. Translation: the drug works better when paired with consistent dietary changes, and that combination may allow dose reduction over time.

How to Talk to Your Prescriber About Cost

Many patients do not bring up cost during clinical visits, which means they end up on drugs they cannot sustain. A few specific questions help:

1. "Is there a generic version of what you are prescribing?"
2. "Does my insurance formulary cover any weight loss medications, and at what tier?"
3. "Is there a manufacturer patient assistance program I qualify for?"
4. "If I cannot afford the brand, is compounded semaglutide from a 503B facility an option right now given current FDA guidance?"
5. "What is the minimum effective dose I should start with?"

The Obesity Medicine Association's 2023 position statement recommends that clinicians routinely document cost barriers and adjust prescribing accordingly rather than defaulting to the newest branded agent [17].

Special Populations: Who Needs Extra Caution

Patients With Type 2 Diabetes

GLP-1 receptor agonists like semaglutide (Ozempic 0.5 to 2.0 mg, not Wegovy) and liraglutide (Victoza) are approved for diabetes. Insurance coverage for the diabetes indication is substantially better than for the obesity indication. Some patients with both diabetes and obesity are prescribed the diabetes-approved GLP-1 at the highest approved dose, which may produce significant weight loss while costing far less out-of-pocket. Prescribers should document both indications clearly.

Adolescents

The FDA approved Wegovy for adolescents aged 12 and older with obesity in December 2022. For this population, the teen-STEP trial (N=201) showed 16.1% body weight reduction at 68 weeks vs. 0.6% for placebo [18]. Orlistat 120 mg is the only other agent with a pediatric obesity indication (age 12+). Generic phentermine is approved only for adults.

Older Adults (65+)

Phentermine carries cardiovascular risk concerns that make it less suitable for older adults with existing heart disease. Metformin requires dose adjustment for reduced kidney function (eGFR <30 mL/min/1.73 m² is a contraindication). Orlistat's fat-soluble vitamin depletion matters more in older adults already prone to vitamin D and K deficiency. Brand or compounded GLP-1s, if tolerated, tend to have a more favorable risk profile in this group, though nausea management and muscle mass preservation require monitoring.

The Bottom Line on Affordability

Phentermine is the cheapest. At $15 to $30 per month for a Schedule IV generic, no prescription weight loss drug comes close on sticker price. But cheap and cost-effective are not the same thing: if phentermine produces only 4% weight loss and a patient regains it within a year of stopping (which is common, given the lack of long-term approval), the total cost including downstream health consequences may exceed what a more effective drug would have cost upfront.

The Endocrine Society's 2015 Clinical Practice Guideline on pharmacotherapy for obesity states: "Selection of a specific agent should be based on the drug's safety profile, tolerability, and anticipated efficacy for the individual patient, as well as cost" [19]. Cost is explicitly part of evidence-based prescribing. The most affordable drug for a given patient is the one that produces durable weight loss at a price the patient can actually pay every month, not just the one with the lowest list price.

If you have commercial insurance, applying for the Wegovy or Zepbound savings card before assuming you cannot afford it is worth the five-minute online process. If you are paying cash, generic phentermine/topiramate ER for shorter-term goals and compounded semaglutide from a verified 503B facility (while FDA guidance allows it) for longer-term GLP-1-class efficacy represent the two strongest value positions as of mid-2025.